tRNA-yW synthesizing protein 5Genealiases: C2orf60 · hTYW5
Q-omics provides the consensus-scored TYW5 profile across patient tissues and cancer cell-line models. TYW5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TYW5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TYW5 RNA expression shows 21,442 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TYW5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYW5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYW5 survival associations across molecular data types. TYW5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYW5 RNA expression–survival associations across cancer types. High TYW5 expression shows unfavorable associations in ACC, LIHC, KIRC, UVM and LGG, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TYW5 RNA expression.
This table summarizes TYW5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TYW5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYW5 shows higher tumor expression in HNSC, BLCA, LUAD, STAD, LIHC and COAD. The HNSC box plot shows higher TYW5 RNA expression in tumor versus normal tissue (log2 FC = +0.717, t-test p < 0.001).
This table shows molecular features associated with TYW5 in patient tissues and cancer cell lines. In patient samples, TYW5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TYW5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
